DelveInsight’s “Limb-Girdle Muscular Dystrophy (LGMD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Limb-Girdle Muscular Dystrophy Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Limb-Girdle Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Limb-Girdle Muscular Dystrophy (LGMD): An Overview
Limb-girdle muscular dystrophy (LGMD) is a term for a group of diseases that cause weakness and wasting of the muscles in the arms and legs. The muscles most affected are those closest to the body (proximal muscles), specifically the muscles of the shoulders, upper arms, pelvic area, and thighs.
The different subtypes of LGMD can be broadly categorized under two inheritance patterns, autosomal dominant and autosomal recessive. Autosomal means that the genes involved are present on the autosomes or non-sex chromosomes, the X and the Y chromosome. So both males and females have the same probability of developing the disease.
Even though many genes that cause LGMD have been identified, other genes that are thought to be involved in rarer forms of LGMD have yet to be identified.
Limb-Girdle Muscular Dystrophy (LGMD) Market Key Facts
According to the National Institutes of Health, it is difficult to determine the prevalence of limb-girdle muscular dystrophy because its features vary and overlap with those of other muscle disorders. Prevalence estimates range from 1 in 14,500 to 1 in 123,000 individuals.
- According to the National Organization for Rare Disorders, the incidence of the disorder is unknown. The relative frequencies of the different types of LGMD vary from population to population, but worldwide LGMD2G, 2H and 2J are extremely rare.
As per the Orphanet, the estimated prevalence for all forms of LGMD ranges from 1/44,000 to 1/123,000.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Limb-Girdle Muscular Dystrophy market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Limb-Girdle Muscular Dystrophy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Limb-Girdle Muscular Dystrophy (LGMD) Epidemiology Segmentation
Prevalent cases of Limb-Girdle Muscular Dystrophy
Type-specific Prevalent Cases of Limb-Girdle Muscular Dystrophy
Severity-specific Prevalent Cases of Limb-Girdle Muscular Dystrophy
Diagnosed and Treatable Cases of Limb-Girdle Muscular Dystrophy
Limb-Girdle Muscular Dystrophy (LGMD) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Limb-Girdle Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Limb-Girdle Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Limb-Girdle Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market
Limb-Girdle Muscular Dystrophy (LGMD) Therapeutics Analysis
The current pipeline for Limb-Girdle Muscular Dystrophy does not hold many significant products, it has very few products that certain key players are developing. However, the dynamics of the Limb-Girdle Muscular Dystrophy market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies.
Some of the key companies in the Limb-Girdle Muscular Dystrophy (LGMD) Market include:
aTyr Pharma, Inc.
Sarepta Therapeutics, Inc.
And many others
Limb-Girdle Muscular Dystrophy (LGMD) Therapies covered in the report:
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Limb-Girdle Muscular Dystrophy Competitive Intelligence Analysis
4. Limb-Girdle Muscular Dystrophy Market Overview at a Glance
5. Limb-Girdle Muscular Dystrophy Disease Background and Overview
6. Limb-Girdle Muscular Dystrophy Patient Journey
7. Limb-Girdle Muscular Dystrophy Epidemiology and Patient Population
8. Limb-Girdle Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Limb-Girdle Muscular Dystrophy Unmet Needs
10. Key Endpoints of Limb-Girdle Muscular Dystrophy Treatment
11. Limb-Girdle Muscular Dystrophy Marketed Products
12. Limb-Girdle Muscular Dystrophy Emerging Therapies
13. Limb-Girdle Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Limb-Girdle Muscular Dystrophy Market Outlook (7 major markets)
16. Limb-Girdle Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Limb-Girdle Muscular Dystrophy Market.
18. Limb-Girdle Muscular Dystrophy Market Drivers
19. Limb-Girdle Muscular Dystrophy Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Report by DelveInsight
“Hematuria Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Hematuria Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the Hematuria therapeutics Market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States